CTLA4 and neoplasm: Pioneering work from Jim Allison and co-workers in the mid-1990s showed that antibodies blocking CTLA-4 were able to enhance the anti-tumor immune response in mice, resulting in complete tumor rejection and long-lasting immunity [2].